KR102559354B1 - 치매 치료 - Google Patents
치매 치료 Download PDFInfo
- Publication number
- KR102559354B1 KR102559354B1 KR1020197009175A KR20197009175A KR102559354B1 KR 102559354 B1 KR102559354 B1 KR 102559354B1 KR 1020197009175 A KR1020197009175 A KR 1020197009175A KR 20197009175 A KR20197009175 A KR 20197009175A KR 102559354 B1 KR102559354 B1 KR 102559354B1
- Authority
- KR
- South Korea
- Prior art keywords
- delete delete
- compound
- ftld
- acid
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
- Medicinal Preparation (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
- Valve Device For Special Equipments (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1614834.8 | 2016-09-01 | ||
| GBGB1614834.8A GB201614834D0 (en) | 2016-09-01 | 2016-09-01 | Treatment of dementia |
| PCT/EP2017/071437 WO2018041739A1 (en) | 2016-09-01 | 2017-08-25 | Treatment of dementia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20190045273A KR20190045273A (ko) | 2019-05-02 |
| KR102559354B1 true KR102559354B1 (ko) | 2023-07-26 |
Family
ID=57139937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020197009175A Active KR102559354B1 (ko) | 2016-09-01 | 2017-08-25 | 치매 치료 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US10842796B2 (https=) |
| EP (1) | EP3506904B1 (https=) |
| JP (1) | JP7066679B2 (https=) |
| KR (1) | KR102559354B1 (https=) |
| CN (1) | CN109890391B (https=) |
| AU (1) | AU2017318333B2 (https=) |
| DK (1) | DK3506904T3 (https=) |
| ES (1) | ES2847929T3 (https=) |
| GB (1) | GB201614834D0 (https=) |
| HR (1) | HRP20210162T1 (https=) |
| MX (1) | MX384442B (https=) |
| MY (1) | MY187564A (https=) |
| PL (1) | PL3506904T3 (https=) |
| PT (1) | PT3506904T (https=) |
| SG (1) | SG11201901125TA (https=) |
| SI (1) | SI3506904T1 (https=) |
| WO (1) | WO2018041739A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2013191B3 (en) | 2006-03-29 | 2019-02-27 | Wista Laboratories Ltd. | 3,7-diamino-10h-phenothiazine salts and their use |
| DK3121169T3 (da) | 2006-07-11 | 2022-02-28 | Wista Lab Ltd | Fremgangsmåder til syntese og/eller oprensning af diaminophenothiaziniumforbindelser |
| KR102592614B1 (ko) | 2016-07-25 | 2023-10-24 | 위스타 레보레이토리스 리미티드 | 디아미노페노티아진 (diaminophenothiazines)의 투여 및 투여량 (dosage) |
| DK3826639T3 (da) * | 2018-07-26 | 2024-09-23 | Wista Lab Ltd | Optimeret dosering af diaminophenothiaziner i populationer |
| WO2020048593A1 (en) | 2018-09-05 | 2020-03-12 | Wista Laboratories Ltd. | Network methods for neurodegenerative diseases |
| GB201909493D0 (en) | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Therapeutic interactions |
| GB201909454D0 (en) | 2019-07-01 | 2019-08-14 | Wista Lab Ltd | Enhancers |
| GB201909506D0 (en) | 2019-07-02 | 2019-08-14 | Wista Lab Ltd | Synaptopathies |
| JP2023524146A (ja) * | 2020-05-05 | 2023-06-08 | ウィスタ ラボラトリーズ リミテッド | 低酸素血症の治療に使用されるメチルチオニニウム化合物 |
| GB202006659D0 (en) * | 2020-05-05 | 2020-06-17 | Wista Lab Ltd | Therapeutic treatments |
| WO2023232764A1 (en) | 2022-05-31 | 2023-12-07 | Wista Laboratories Ltd. | Treatment of neurodegenerative disorders utilising methylthioninium (mt)-containing compounds |
| EP4342451A1 (en) * | 2022-09-22 | 2024-03-27 | Galenicum Health SLU | Pharmaceutical compositions and manufacturing methods thereof |
| US20240115579A1 (en) * | 2022-09-22 | 2024-04-11 | Galenicum Health S.L.U. | Pharmaceutical compositions and manufacturing methods thereof |
| WO2024178120A2 (en) * | 2023-02-21 | 2024-08-29 | Prosetta Biosciences, Inc. | Phenothiazinyl compounds and uses |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012107706A1 (en) | 2011-02-11 | 2012-08-16 | Wista Laboratories Ltd. | Phenothiazine diaminium salts and their use |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9506197D0 (en) | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
| GB0101049D0 (en) | 2001-01-15 | 2001-02-28 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| WO2003101458A1 (en) | 2002-05-31 | 2003-12-11 | H. Lundbeck A/S | A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease |
| AU2005286235C1 (en) | 2004-09-23 | 2013-08-22 | TauRx Therapeutics Management Ltd | Methods of chemical synthesis and purification of diaminophenothiazinium compounds including Methylthioninium Chloride (MTC) |
| EP2013191B3 (en) * | 2006-03-29 | 2019-02-27 | Wista Laboratories Ltd. | 3,7-diamino-10h-phenothiazine salts and their use |
| MY162640A (en) * | 2006-03-29 | 2017-06-30 | Wista Lab Ltd | Thioninium compounds and their use |
| FR2899107B1 (fr) * | 2006-03-30 | 2008-06-13 | Neurokin Entpr Unipersonnelle | Utilisation de la (s)-roscovitine pour la fabrication d'un medicament |
| DK3121169T3 (da) | 2006-07-11 | 2022-02-28 | Wista Lab Ltd | Fremgangsmåder til syntese og/eller oprensning af diaminophenothiaziniumforbindelser |
| FR2903696B1 (fr) | 2006-07-12 | 2011-02-11 | Provence Technologies | Procede de purification de composes diaminophenothiazium |
| US9034890B2 (en) * | 2006-11-15 | 2015-05-19 | Steven A. Rich | Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases |
| CN101820884B (zh) | 2007-06-19 | 2013-08-28 | 维斯塔实验室有限公司 | 用于治疗轻度认知缺损的吩噻嗪化合物 |
| CA3027974C (en) | 2007-10-03 | 2022-03-15 | Wista Laboratories Ltd. | Therapeutic use of diaminophenothiazines |
| DK3378856T3 (da) | 2009-09-24 | 2020-12-21 | Wista Lab Ltd | Krystallinske methylthioniniumchlorid-hydrater |
| PL2480540T3 (pl) | 2009-09-24 | 2018-05-30 | Wista Laboratories Ltd. | Pentahydrat chlorku metylotioninowego, jego wytwarzanie i zastosowanie farmaceutyczne |
| CN102936244B (zh) * | 2012-12-04 | 2015-02-04 | 合肥工业大学 | 一种他克林-吩噻嗪异二联体类化合物及其制备方法 |
-
2016
- 2016-09-01 GB GBGB1614834.8A patent/GB201614834D0/en not_active Ceased
-
2017
- 2017-08-25 PL PL17761842T patent/PL3506904T3/pl unknown
- 2017-08-25 ES ES17761842T patent/ES2847929T3/es active Active
- 2017-08-25 SG SG11201901125TA patent/SG11201901125TA/en unknown
- 2017-08-25 JP JP2019511720A patent/JP7066679B2/ja active Active
- 2017-08-25 DK DK17761842.8T patent/DK3506904T3/da active
- 2017-08-25 US US16/329,611 patent/US10842796B2/en active Active
- 2017-08-25 MY MYPI2019001119A patent/MY187564A/en unknown
- 2017-08-25 WO PCT/EP2017/071437 patent/WO2018041739A1/en not_active Ceased
- 2017-08-25 AU AU2017318333A patent/AU2017318333B2/en active Active
- 2017-08-25 CN CN201780067154.4A patent/CN109890391B/zh active Active
- 2017-08-25 EP EP17761842.8A patent/EP3506904B1/en active Active
- 2017-08-25 MX MX2019002429A patent/MX384442B/es unknown
- 2017-08-25 SI SI201730630T patent/SI3506904T1/sl unknown
- 2017-08-25 KR KR1020197009175A patent/KR102559354B1/ko active Active
- 2017-08-25 HR HRP20210162TT patent/HRP20210162T1/hr unknown
- 2017-08-25 PT PT177618428T patent/PT3506904T/pt unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012107706A1 (en) | 2011-02-11 | 2012-08-16 | Wista Laboratories Ltd. | Phenothiazine diaminium salts and their use |
Also Published As
| Publication number | Publication date |
|---|---|
| US20190192530A1 (en) | 2019-06-27 |
| KR20190045273A (ko) | 2019-05-02 |
| AU2017318333B2 (en) | 2023-05-11 |
| WO2018041739A1 (en) | 2018-03-08 |
| JP2019526571A (ja) | 2019-09-19 |
| US10842796B2 (en) | 2020-11-24 |
| SI3506904T1 (sl) | 2021-03-31 |
| SG11201901125TA (en) | 2019-03-28 |
| EP3506904B1 (en) | 2020-12-09 |
| PL3506904T3 (pl) | 2021-07-26 |
| HRP20210162T1 (hr) | 2021-03-19 |
| EP3506904A1 (en) | 2019-07-10 |
| CA3034625A1 (en) | 2018-03-08 |
| CN109890391B (zh) | 2023-01-31 |
| GB201614834D0 (en) | 2016-10-19 |
| MY187564A (en) | 2021-09-30 |
| CN109890391A (zh) | 2019-06-14 |
| MX384442B (es) | 2025-03-14 |
| AU2017318333A1 (en) | 2019-04-18 |
| MX2019002429A (es) | 2019-07-08 |
| DK3506904T3 (da) | 2021-01-04 |
| JP7066679B2 (ja) | 2022-05-13 |
| PT3506904T (pt) | 2021-02-02 |
| ES2847929T3 (es) | 2021-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102559354B1 (ko) | 치매 치료 | |
| AU2025210905A1 (en) | Method of treatment with tradipitant | |
| AU2020298737B2 (en) | Methylthioninium as enhancers of the cognitive function | |
| AU2010282509B2 (en) | Use of 4-aminopyridine to improve neuro-cognitive and/or neuro-psychiatric impairment in patients with demyelinating and other nervous system conditions | |
| KR20070084123A (ko) | 양극성 장애 및 관련 증상의 치료 | |
| JP2022538642A (ja) | ロイコメチルチオニニウムの治療上の相互作用 | |
| JP7695724B2 (ja) | 医薬組成物およびその適用 | |
| CA3034625C (en) | Treatment of dementia | |
| RU2277096C2 (ru) | Средства против слабоумия, содержащие производное 2-арил-8-оксодигидропурина в качестве активного ингредиента | |
| HK40003690A (en) | Treatment of dementia | |
| HK40003690B (en) | Treatment of dementia | |
| AU2018258970B2 (en) | Idalopirdine-based combinatorial therapies of Alzheimer's disease | |
| JP2025500088A (ja) | Ｆｅｎｍ及びアセチルコリンエステラーゼ阻害剤をベースとする新規相乗的組合せ | |
| CN116635034A (zh) | 用于治疗人低胆碱能障碍的药物组合 | |
| HK40071167A (en) | Methods for treating behavioral and psychological symptoms in patients with dementia | |
| HK40071665A (en) | Treating behavioral and psychological symptoms in dementia patients | |
| JP2023544224A (ja) | ヒト低コリン作動性障害の処置のための医薬の組合せ | |
| CN117529318A (zh) | 治疗阿尔茨海默病的方法 | |
| CN114761008A (zh) | 用于在患有痴呆的患者中治疗行为和心理症状的方法 | |
| CN114901282A (zh) | 在痴呆患者中治疗行为和精神症状 | |
| EP3746062A1 (en) | Baclofen and acamprosate based therapy of alzheimer's disease in patients having lost responsiveness to acetylcholinesterase inhibitor therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| AMND | Amendment | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| AMND | Amendment | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |
|
| AMND | Amendment | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PX0901 | Re-examination |
St.27 status event code: A-2-3-E10-E12-rex-PX0901 |
|
| PX0701 | Decision of registration after re-examination |
St.27 status event code: A-3-4-F10-F13-rex-PX0701 |
|
| X701 | Decision to grant (after re-examination) | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| R18 | Changes to party contact information recorded |
Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |